| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/18/2005 | CA2169603C Retrovirus from the hiv group and its use |
| 01/18/2005 | CA2144043C Human neutralizing monoclonal antibodies to respiratory syncytial virus |
| 01/14/2005 | CA2454540A1 Method for inducing hepatitis c virus (hcv) replication in vitro, cells and cell lines enabling robust hcv replication and kit thereof |
| 01/14/2005 | CA2436104A1 Method for inducing hepatitis c virus (hcv) replication in vitro, cells and cell lines enabling robust hcv replication and kit therefor |
| 01/13/2005 | WO2005003775A2 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri |
| 01/13/2005 | WO2005003330A2 Acapsular p. multocida hyae deletion mutants |
| 01/13/2005 | WO2005003325A2 Inhibition of viral pathogenesis |
| 01/13/2005 | WO2005003302A2 Novel methods to modulate mast cells |
| 01/13/2005 | WO2005003295A2 Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds |
| 01/13/2005 | WO2005002621A2 Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
| 01/13/2005 | WO2005002620A1 Quil a fraction with low toxicity and use thereof |
| 01/13/2005 | WO2005002619A2 Immunogenic compositions for chlamydia trachomatis |
| 01/13/2005 | WO2005002618A1 Vaccine composition for vaccinating dogs against canine infectious respiratory disease (cird) |
| 01/13/2005 | WO2005002570A1 Use of an aziridino compound to selectively inactivate parasites in biological compositions |
| 01/13/2005 | WO2005002515A2 Delivery of therapeutic compounds to the brain and other tissues |
| 01/13/2005 | WO2005002513A2 C1q complement inhibitors and methods of use thereof |
| 01/13/2005 | WO2005002512A2 Immunotherapeutic vaccine strategy |
| 01/13/2005 | WO2005002505A2 Apolipoprotein c-1 induced apoptosis |
| 01/13/2005 | WO2005002502A2 An assay for detecting the presence of processing inhibitory antibodies against the apical membrane antigene-1 of plasmodium falciparum in biological samples |
| 01/13/2005 | WO2005002501A2 Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same |
| 01/13/2005 | WO2005002500A2 Inhibitors of coronavirus |
| 01/13/2005 | WO2004099422A3 Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
| 01/13/2005 | WO2004094639A3 Recombinant fel d 1 allergen |
| 01/13/2005 | WO2004082568A3 Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar) |
| 01/13/2005 | WO2004080375A3 Vaccine therapy of atherosclerosis |
| 01/13/2005 | WO2004074321A3 Therapeutic gpcr targets in cancer |
| 01/13/2005 | WO2004069876A3 Trimeric polypeptide construct to induce an enduring t cell response |
| 01/13/2005 | WO2004043141A3 Novel inhibin-related multiple antigenic peptide compositions that enhance production performance in avians |
| 01/13/2005 | WO2004035003A3 Therapeutic adjuvant |
| 01/13/2005 | WO2004031230A3 Novel mhc ii associated peptides |
| 01/13/2005 | WO2004030613A3 Cancer therapy using beta glucan and antibodies |
| 01/13/2005 | WO2004027381A3 Methods and compositions related to inhibiting nuclear envelope breakdown |
| 01/13/2005 | WO2004024097A8 Compositions and methods for the treatment of immune related diseases |
| 01/13/2005 | WO2003089569A3 Use of il-19, il-22 and il-24 to treat hematopoietic disorders |
| 01/13/2005 | WO2003074073A3 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof |
| 01/13/2005 | WO2003072715A8 Gasp1: a follistatin domain containing protein |
| 01/13/2005 | WO2003065787A8 Methods and compositions for the targeting of a systemic immune response to specific organs or tissues |
| 01/13/2005 | WO2002092001A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/13/2005 | US20050010043 Recombinant flavivirus for use in generation of vaccines to prevent and treat hemorrhagic fever |
| 01/13/2005 | US20050010041 Bacterial gene and method of treating a gram negative bacterial infection |
| 01/13/2005 | US20050010034 Pyrogenic exotoxin type C (SPE-C) protein for use in generating vaccine for use in prevention of streptocccal infection/poisioning |
| 01/13/2005 | US20050010033 Pyrogenic exotoxin type C (SPE-C) protein for use in generating vaccine for use in prevention of streptocccal infection/poisioning |
| 01/13/2005 | US20050010032 Vaccine for periodontal disease |
| 01/13/2005 | US20050010030 Nucleotide sequences comprising lymphocyte receptor for use in generating immunoglobulin which suppress or prevent activation or proliferation of v-beta response; immunotherapy and treatment of joint inflammation |
| 01/13/2005 | US20050009774 Immunomodulatory oligonucleotides |
| 01/13/2005 | US20050009770 Use of excipients to increase DNA uptake by swine muscle cells |
| 01/13/2005 | US20050009740 Mixture of carrier, target peptide and immune response triggers |
| 01/13/2005 | US20050009188 Animal immunocontraceptives expressed in plants and uses thereof |
| 01/13/2005 | US20050009150 Humanized antibodies that recognize beta amyloid peptide |
| 01/13/2005 | US20050009144 Transgenic cell comprising nucleotide sequences coding endostatins for use as tool in identifying modulators for treatment and prevention of cell proliferative and angiogenesis-related disorders |
| 01/13/2005 | US20050009141 Epidermal differentiation factor |
| 01/13/2005 | US20050009119 Using expression of intracellular protein on surface of damaged and/or tumor cells as diagnostic/prognostic indicator of drug resistance; immunotherapy; antitumor agents; genetic vaccines |
| 01/13/2005 | US20050009106 Mammalian cytokine; related reagents |
| 01/13/2005 | US20050009105 Compositions and methods for the diagnosis and treatment of tumor |
| 01/13/2005 | US20050009062 Phosphodiesterase 10 |
| 01/13/2005 | US20050009057 Using apical membrane antigen-1 as a diagnostic and therapeutic aide in treatment and prevention of plasmodium infection; immunotherapy; antimalarial agents |
| 01/13/2005 | US20050009008 Functional influenza virus-like particles (VLPs) |
| 01/13/2005 | US20050008688 Oral administering; tablet with enteric coating; supplying drug to gastrointestinal systems |
| 01/13/2005 | US20050008685 Mixture containing liposome electrolytes |
| 01/13/2005 | US20050008659 Prevention, therapy of Eimeria infections; induction resistance to coccidiosis |
| 01/13/2005 | US20050008658 Enterococcus antigens and vaccines |
| 01/13/2005 | US20050008654 For prevention, therapy of sepsis shock, thrombosis disorders |
| 01/13/2005 | US20050008651 Modulating replication via immunogen and pharmaceutically or veterinarily acceptable vehicles |
| 01/13/2005 | US20050008650 Chemical modification of single chain polypeptides by means of covalent attachment of strands of polyethylene glycol to single chain polypeptide binding molecules that have three dimensional folding and binding ability |
| 01/13/2005 | US20050008648 Mutant kinase; anticancer agents; supplying to leukemia blastocytes; antibody which detects cell surface antigen; antiproliferative agent |
| 01/13/2005 | US20050008645 Antibodies Specific For Phosphatase Subunit of LAR |
| 01/13/2005 | US20050008644 Potentiation of the immune response |
| 01/13/2005 | US20050008643 Diagnostic methods and agents |
| 01/13/2005 | US20050008641 Composition for neuronal regeneration comprising myelin-specific antibodies and complement proteins |
| 01/13/2005 | US20050008640 Method of treating transplant rejection |
| 01/13/2005 | US20050008637 Cancer therapy; antiinflammatory agents; autoimmune disease |
| 01/13/2005 | US20050008636 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| 01/13/2005 | US20050008635 Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods |
| 01/13/2005 | US20050008634 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| 01/13/2005 | US20050008633 Chemical and physical modulators of bioavailability of inhaled compositions |
| 01/13/2005 | US20050008623 In vitro production of dendritic cells from CD14+ monocytes |
| 01/13/2005 | US20050008618 Composition for delivering an agent to a target cell and uses thereof |
| 01/13/2005 | CA2563362A1 Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds |
| 01/13/2005 | CA2531321A1 Rna processing protein complexes and uses thereof |
| 01/13/2005 | CA2531023A1 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri |
| 01/13/2005 | CA2530797A1 Vaccine composition for vaccinating dogs against canine infectious respiratory disease (cird) |
| 01/13/2005 | CA2529363A1 Quil a fraction with low toxicity and use thereof |
| 01/13/2005 | CA2529057A1 Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
| 01/13/2005 | CA2528860A1 Recombinant antibodies and compositions and methods for making and using the same |
| 01/13/2005 | CA2528551A1 Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| 01/13/2005 | CA2528084A1 Sppls as modifiers of the p53 pathway and methods of use |
| 01/13/2005 | CA2527908A1 Mylks as modifiers of branching morphogenesis and methods of use |
| 01/13/2005 | CA2527905A1 Nadks as modifiers of branching morphogenesis and methods of use |
| 01/13/2005 | CA2527866A1 Modified antibody fragments |
| 01/13/2005 | CA2527373A1 Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease |
| 01/13/2005 | CA2527020A1 Modified antibody fab fragments |
| 01/13/2005 | CA2526106A1 Immunogenic compositions for chlamydia trachomatis |
| 01/13/2005 | CA2525236A1 Delivery of therapeutic compounds to the brain and other tissues |
| 01/13/2005 | CA2522329A1 Inhibitors of coronavirus |
| 01/13/2005 | CA2518716A1 Inhibition of viral pathogenesis |
| 01/12/2005 | EP1496364A2 Cloning and expression of gonadotropin-releasing hormone receptor |
| 01/12/2005 | EP1495767A1 Immunoadjuvant |
| 01/12/2005 | EP1495322A2 Heteroclitic analogs and related methods |
| 01/12/2005 | EP1495130A1 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 01/12/2005 | EP1495123A1 Erbb3 based methods and compositions for treating neoplasms |